Dana Rabara
Leidos (United States)(US)Frederick Community College(US)Frederick National Laboratory for Cancer Research(US)Science Applications International Corporation (United States)(US)
Publications by Year
Research Areas
Protein Kinase Regulation and GTPase Signaling, Cancer, Hypoxia, and Metabolism, Nitric Oxide and Endothelin Effects, Metabolism, Diabetes, and Cancer, Enzyme Structure and Function
Most-Cited Works
- → KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis(2019)122 cited
- → Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer(2019)43 cited
- → Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C(2024)35 cited
- → Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31P NMR(2024)20 cited
- → BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction(2025)16 cited
- → Abstract ND07: BBO-8520, a first-in-class, direct inhibitor of KRASG12C (ON), locks GTP-bound KRASG12C in the state 1 conformation resulting in rapid and complete blockade of effector binding(2024)